Clinical Trials Logo

Heart Valve Disease clinical trials

View clinical trials related to Heart Valve Disease.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03928639 Withdrawn - Heart Failure Clinical Trials

Structural Heart and Valve Network PROSPECTIVE Registry

Start date: January 10, 2023
Phase:
Study type: Observational

Background: Treatments for structural heart and valve disease are quickly changing. But treatment could be improved. Researchers want to gather data from people with this disease. They want to find problems and seek new ways to make treatments better. Objective: To find people with structural heart and valve disease with common features to study. To find flaws and patterns in procedures related to this disease. To share findings with other researchers. Eligibility: People ages 18 and older who are receiving care from the structural heart and valve program at the participating NHLBI structural heart disease network sites that are part of the study Design: Participants will be screened with their consent. This will occur when they give their standard consent for medical care. Participants will have their data collected in the course of standard medical care. Data include: Demographic data Protected health data Personally identifiable data Medical records Medical images. These could include X-rays, CT scans, and MRI scans. The study could find something that would impact participants care. If this is the case, their doctors will be told. Participants data may be shared with other researchers. ...

NCT ID: NCT00187304 Withdrawn - Heart Valve Disease Clinical Trials

ACTION - Anticoagulation Treatment Influence on Post-operative Patients

Start date: September 2005
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to compare two different regimens of therapy, AVK and ASA (aspirin), in the early postoperative period after aortic valve replacement with SJM Epicâ„¢ or SJM Epicâ„¢ Supra Porcine Bioprosthetic Heart Valve by establishing the adverse event free survival rate at 3 month post intervention follow-up of the 2 groups(with special focus on thromboembolic events and bleedings).